US3072527A - Use of tolbutamide in the treatment of acne - Google Patents

Use of tolbutamide in the treatment of acne Download PDF

Info

Publication number
US3072527A
US3072527A US82417659A US3072527A US 3072527 A US3072527 A US 3072527A US 82417659 A US82417659 A US 82417659A US 3072527 A US3072527 A US 3072527A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
acne
tolbutamide
therapy
lesions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Cohen Fannye Elaine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horner Frank W Ltd
Original Assignee
Horner Frank W Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides

Description

United States Patent '0 USE OF TOLBUTAMIDE IN THE TREATMENT 0F ACNE Jacob Louis Cohen, Windsor,'0ntario, Canada; Fannye Elaine Cohen, administratrix of the estate of said Jacob Louis Cohen, deceased, assignor to Frank W. 7 Horner, Limited, Mount Royal, Quebec, Canada, a

body politic and corporate No Drawing. Filed July 1, 1959, Ser. No. 824,17 4Claims. (Cl. 167-51.5)

This invention relates to an improved method in the treatment of acne particularly pustular acne and more particularly to the treatment of acne by means of an orally ingested drug, tolbutamide.

The treatment of acne is not a simple magic bullet afiair. In severe cases of acute pustular acne, local therapy alone is of little value. The specific systemic measures usually employed in addition to local therapy depend upon the seriousness of the skin condition. Additional measures which have been used in the past include: hormone therapy, particularly diethylstilboestrol; dietary control; vitamin'supplements, particularly vitamin A and vitamin C; ultra-violet and X-ray therapy; administration of toxoids and vaccines; and use of antibiotics, such as Sulfonamides; penicillin, erythromycin chloramphenicol, oleandomycin tetracycline and novobiocin. Isoniazid has also been used. f Most consistent results have been achieved with, chloramphenicol and erythromycin. Nevertheless treatment with antibiotics is unsatisfactory since, while a favourable response is usually obtained, this is followed by a new flare-up, and relapses are frequent after discontinuance of the antibiotics. The other forms of drug therapy are alsonot completely effective.

Itis an object of the present invention to provide an improved therapy for the relief of symptoms of acne.

This object is achieved in the method of treating acne which comprises: selecting a human-having acne; and feeding said human a therapeutically efiective dose of tolbutamide. I

Tolbutamide, i.e. a sulfonamide having the formula a o ll cm-Q-somn-o-rrnomir Patented Jan. 8, 1963 ice has been used in the treatment of diabetes mellitus. However it has now been discovered that tolbutamide has unexpected utility in the treatment of acne, since tolbutamide has no bactericidal effect. 7

Usually, the therapy consists in the ingestion, by the patient suffering from acne, of tablets containing tolbutamide. 'Usually a maximum of about 1 gram of tolbutamide per day is given since otherwise there is an unde-' sirable hypoglycemic response in non-diabetic patients suffering from acne. Thus, in dosages of 1.0 gram tolbutamide, blood sugar levels are lowered about 10% in normal individuals. I V

A convenient form of treatment is the use of tablets containing from 0.250 to 1.0 gm. tolbutamide, an especially convenient amount being 0.5 gram tolbutamide per tablet. Preparation of such tablets will be described hereinafter.

A series of patients were treated for acne with tolbut- V amide according to the method of the present invention.

Some patients had deep'pustular acne, chronic staphyloderrna, recurrent furunculosis, sycosis vulgaris, hidra-i denitis suppurativa or hidrosadenitis axillaris, and other resistant pustular infections of the skin.

Only patients who were resistant to therapy by the usual methods of treatment were treated according to the present invention. They were instructed to continue taking carbohydrates in their diet, including candy and fruit if desired. All those patients with severe acne received a tablet containing 0.5 gram tolbutamide every twelve hours, while those patients with milder cases of acne received one tablet containing 0.5 gram tolbutamide once a day.

The patients were seen at regular intervals and their blood sugars were determined at frequent intervals. The results of'the blood sugar tests were always within normal limits. I

The results obtained for the treatment of acne with tolbutamide according to the present invention is summarized below in Table I: e

Table I Results after treatment with tolbutamide (Time Case No Diagnosis Prior Treatment 7 results achieve months Fair Good Excellent Antibiotics, X-ray and local therapy 2 i Elli???ilEEIIIIII:" X-ray and local therapy 1 3- Hidradenitis suppuratlva. Antibiotics, X-ray and local therapy- 3 4 Severe pustular acne vul ari An tibioticsi X-ray therapy 3 5 Papulo-pustnlar acne vulgaris. X-i-ayand oral therlapyu 1 6 Sycosis barbae vulgaris, pustular lesions." Antibiotic X-ray t erapy 7 Acne vulgaris X-ray and local therapy. I 8 Pnstular sycosis barbae k-ray, local therapy, antibiotics 2 9 Very severe pustular acne X-ray therapv, local treatrr ent. 10 Deep pustular acne An tibtotics, X-ray and local therapy 2 l1 Cystic, pustular acne vulgar-is. X-ray and local therapy..- 2 l2 ieverle pustlulilr acne vulizarls i.;ay t t. p 3

a u ous ar acne vu ans ii De p pdstular acne X-rady, local therapy, antibio ics 2 3 1 ev I a is... 0.--- l d i P1 at am u g r X-ray and local tberapy 1 l7 Severe pustular acne vulearis X-raytherapy and antibiotics 3 2 '18 Rosacea with acneitorrn lesions; Antibiotics, local and X-ray therapy. I 19 Pustiular acne vulgaris X-rfig; and local therapy 1 0 2 Acne rosacea X-ra? therapy and antibiotics 2 22. %evere pufstilalar acne- "n g. 3 v 4 3 cc usuaracne I g4 Acn fosacea with deep;1 acii Orm lesions X-ray and local therapy, antibio i 4 and moderate rbinoD ma. syc sis barbae vulcarisu i X-raytherapy and antibio cs 3 Iustularacne vulgaris X-ray therapy. 1 2

1 Nausea. and diarrhoea.

It is seen from the above table that all patients experienced improvement following treatment with tolbutamide according to t e teachings of the present invention. No hypoglycemic reactions were observed.

The following case reports are intended to describe more completely the beneficial results following treatment with tolbutamide following the teachings of the present invention.

Case 3.Mrs. M. C. (practical nurse), aged 50, with a long history of recurrent furunculosis involving groin, external genitalia, breast and nipple areas, was treated by incision and drainage and X-ray therapy, and was allergic to many antibiotics except oleandomycin and erythromycin. She had many recurrent flare-ups. She was first seen with subcutaneous nodular, painful lesions, involving groin and perianal and vulvar regions, as well as a few in the axillae. Some were soft and fluctuating and discharged purulent material which on culture grew a haemolytic staphylococcus. The diagnosis was: hidradenitis suppurativa, or deep infection of the apocrine glands. Treatment included more X-ray therapy, ultraviolet light, antiseptic compresses and applications, tin oxide tablets, oestrogenic hormone, staphylococcus toxoid, and multiple vaccine therapy. She responded very well to erythromycin and oleandomycin, but with flare-ups of painful and recurrent furuncular lesions. The fasting blood sugar was 95 mg. percent and she had no glycosuria. She was then started on tolbutamide, 0.5 g., twice a day, and gradually showed a marked improvement with only occasional recurrences. The subcutaneous nodules did not develop into abscesses and underwent resolution. She is taking one tolbutamide tablet daily.

Case 4.Mr. H. D., aged 20 (farmer), was first seen with a very severe and deep cystic and papulo-pustular acne vulgaris, and an associated oily seborrhoea. Face and forehead were covered with reddened cystic and deep acne pustular lesions, and many indurated papules. Some cysts were the size of a hazel nut and one was the size of a small walnut. He had been under the care of dermatologists for four years, and received much X-ray and local therapy.

He was then given more unfiltered X-ray therapy, Vleminckxs compresses, detergent soaps, staphylococcus toxoid, sulphur and resorcin cream and lotion, and a variety of antibiotics from sulfonamides to all the mycins, responding best to chloramphenicol. There were many remissions and relapses. All therapy was stopped except local therapy and he was started on tolbutamide, 0.5 g. twice a day. Hewas instructed to take a little extra candy each day, and was given CO therapy with acetone locally twice weekly. The response was sudden and dramatic. In two weeks, all pustular elements of the lesions disappeared. The active lesions subsided markedly and no new lesions appeared. He is being treated now for the late sequelae, and a few very superificial pustules still make their appearance. He is taking one tolbutamide tablet daily.

Case 9.-Mr. D. I. (mechanic), aged 22, had been treated for acne for five years at other centres and had received about 1000 r. of X-ray therapy. He was first .seen presenting a deep cystic type of acne vulgaris of the face, shoulders and back, with innumerable sebaceous cysts and cornedones and deep acne papulo-pustules. The reddened cysts were the size of a hazel nut, and the neck was involved with band-like keloidal lesions. He felt very insecure and afraid to face the public, and required tranquillizers. This patient had been treated by us by all known methods of acne therapy, including diet, Vleminckxs packs, resorcin, and sulphur lotions, stilboestrol and most of the antibiotics. He responded to acne surgery and chloramphenicol, injections of staphylococcal toxoid, vitamins, and ultraviolet light, but with relapses. He was then given tolbutamide, 0.5 g., twice daily. He began to show very marked and continued improvement. The purulent lesions diminished gradually until no evidence of pyoderma was seen, but only acne sequelae with scarring.

Case 22.-Mr. J. H., aged 22 (school teacher), whose acne began at age 15, presented himself to us with a severe deep papulo-pustular acne vulgaris covering the entire back, face, shoulders and chest, with scarring and sequelae. Clinically, this was a case of acne aggregata seu conglobata. Many double comedones with severe perifollicular infection and confluent infiltration, and softening of the lesions with suppuration were present, lesions varying in size from a filbert nut to a marble and requiring many incisions and drainages. Under the care of another dermatologist for 3-4 years previously, he had received maximum doses of X-ray therapy to face, chest and back.

He was also given an acne diet and Vleminckxs packs, resorcin and sulphur lotions, stilboestrol, nearly all known antibiotics, injections of toxoid, and ultraviolet light, and all foci of infection were searched for. He would improve in the summertime with exposure to sunlight, but relapse in the winter with severe and deep pustular lesions. The patient was then given CO therapy to the face and ultraviolet light to the body, injections of multiple vitamins, and one tolbutamide tablet, 0.5 g. twice a day, with a decided and marked improvement of all pustular elements. Local therapy was continued. A few lesions recurred when the patient could not afford medication, but when tolbutamide tablets were supplied to him the lesions gradually subsided. He is now taking one tolbutamide tablet daily with a dramatic subsidence of all lesions, except for the sequelae. Tolbutamide tablets will be stopped when no new lesions appear.

Case 27.-Mrs. M. N. (a stenographer) had been treated for pyoderma faciale, consisting of intense reddish cyanotic erythema associated with superficial and deep abscesses and cystic lesions. Some cysts were connected with communicating channels and sinus tracts with deepseated pustular and linear scarring. Previous treatment consisted of incision and drainage, X-ray therapy, local therapy, injections of penicillin, sulfonamides, many antibiotics including chloramphenicol, ultraviolet light, CO, therapy, vitamins, staphylococcal toxoid, and vitamin D and a search had been made for foci of infection. She had many remissions and relapses with pustular flare-ups. She was then given tolbutamide, with a gradual clearance of all pustular lesions. All lesions have cleared except the late sequelae.

Case 28.Mr. J. L., age 29 (druggi'st), was first seen with a severe papulo-pustular acne vulgaris of face and neck and acne keloidal lesions of the back, deep-seated pustules and many cystic pustular lesions. He also had sycosis vulgaris. This patient had been under the care of other clinicians including dermatologists for many years, receiving X-ray therapy to the limit of tolerance. Under our care he was given acne surgery, ultra-violet light, CO staphylococcus toxoid and all forms of local therapy, resorcin and sulphur lotion, vitamins A and C, isoniazid, stilboestrol, and a large number of antibiotics, with relapses and remissions. He was then started on tolbutamidle 0.5 g. twice daily, with a continued clearance of the lesions. He is still taking one tablet daily, and the lesions have cleared, only an occasional one reappearing. He is now being treated for the last sequelae.

The following example is given to show the preparation of a dosage unit form composition for use in the present invention.

Example 1: T ablets.-12.5 gms. of tolbutamide was thoroughly mixed with .25 gm. orange coloured starch. The mixture was then granulated with a small amount of 24% aqueous solution of gelatin and acacia containing 0.00625 gram of D and C Orange #4, 13.75 grams of orange coloured starch, 7.75 grams sodium bicarbonate and 2.0 grams magnesium stearate were then added. The mixture was then compressed into pellets, each weighing 620 mg.

The proportions used are sufiicient to produce 25 tablets, each containing 0.5 gm. tolbutamide.

Example 2: Capsules-Capsules containing 500 mg. of tolbutamide were prepared by mixing 500 mg. tolbutamide with 10 mg. of light mineral oil, and filled into hard gelatin capsules.

While the above examples show the tolbutamide being in admixture with starch as the diluent, other well-known diluents may also, of course be used. Also dosage unit forms other tablets, for example capsules, may be used.

In summary, therefore, the present invention provides an adjuvant in the treatment of acne. It has been found that the effects on acne (pustular) are usually better than those of the broad-spectrum antibiotics. In most patients good or excellent results were achieved.

What I claim is:

1. The method of treating acne which comprises the steps of (1) selecting a human afllicted with acne, and (2) feeding said human a therapeutically efiective dose of a sulfonamide having the structure:

2. The method of claim 1 wherein the maximum daily dose of the sulfonamide fed is about 3 gms.

3. The method of claim 1 wherein the sulfonamide is fed in a dosage unit form containing about 0.5 gram of said sulfonamide.

4. The method of claim 3 wherein the sulfonamide is fed in tablet form.

References Cited in the file of this patent UNITED STATES PATENTS 2,901,475 Rudner et al Aug. 25, 1959 OTHER REFERENCES Lesser: Drug and Cosmetic Ind., 63:4, October 1948, pp. 465-468, 543-548.

I.A.M.A., Ju1y20, 1957, pp. 1333-1335, vol. 164, No. 12.

Strakosch: AM. and C.T., vol. VI, No. 1, January 1959, pp. 41-46 (received for pub. October 13, 1958).

The Merck Manual, Eighth Ed., 1950, Merck and Co., Inc., Rahway, N.J., page 1314.

Claims (1)

1. THE METHOD OF TREATING ACNE WHICH COMPRISES THE STEPS OF (1) SELECTING A HUMAN AFFLICTED WITH ACNE, AND (2) FEEDING SAID HUMAN A THERAPEUTICALLY EFFECTIVE DOSE OF A SULFONNAMIDE HAVING THE STRUCTURE:
US3072527A 1959-07-01 1959-07-01 Use of tolbutamide in the treatment of acne Expired - Lifetime US3072527A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US3072527A US3072527A (en) 1959-07-01 1959-07-01 Use of tolbutamide in the treatment of acne

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3072527A US3072527A (en) 1959-07-01 1959-07-01 Use of tolbutamide in the treatment of acne

Publications (1)

Publication Number Publication Date
US3072527A true US3072527A (en) 1963-01-08

Family

ID=25240793

Family Applications (1)

Application Number Title Priority Date Filing Date
US3072527A Expired - Lifetime US3072527A (en) 1959-07-01 1959-07-01 Use of tolbutamide in the treatment of acne

Country Status (1)

Country Link
US (1) US3072527A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3144448A (en) * 1964-08-11 Isoxazole derivatives of sulfanilamide
US3334302A (en) * 1962-07-02 1967-08-01 Snc Science Union Et Cie Soc F Dicyclic sulfonylurea compounds
WO2003003971A2 (en) * 2001-06-20 2003-01-16 Merck Sante Use of antidiabetics for making a medicine with cicatrizing effect
US20040147430A1 (en) * 2001-06-02 2004-07-29 Philippe Briet Use of antidiabetics for making a medicine with cicatrizing effect
US20050239887A1 (en) * 2002-01-25 2005-10-27 Ochoa Jose Manuel Francisco L Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
US20050257810A1 (en) * 2001-02-15 2005-11-24 Bigott James W Kitchenware washers and related methods
US20060237046A1 (en) * 2005-04-22 2006-10-26 Bigott James W Kitchenware washers and methods of manufacturing the same
US20060237047A1 (en) * 2001-02-15 2006-10-26 Bigott James W Kitchenware washers and methods of manufacturing the same
US20060237045A1 (en) * 2005-04-22 2006-10-26 Bigott James W Kitchenware washers and methods of manufacturing the same
US20060254619A1 (en) * 2005-04-22 2006-11-16 Bigott James W Commerical kitchenware washers and related methods
US20070264331A1 (en) * 2005-09-08 2007-11-15 Laboratorios Silanes, S.A De C.V. Stable pharmaceutical composition of immediate-release glimepiride and extended-release metformin
US9265400B2 (en) 2005-04-22 2016-02-23 Duke Manufacturing Co. Commercial kitchenware washers and related methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2901475A (en) * 1957-03-04 1959-08-25 Grace W R & Co Chemotherapeutic salts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2901475A (en) * 1957-03-04 1959-08-25 Grace W R & Co Chemotherapeutic salts

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3144448A (en) * 1964-08-11 Isoxazole derivatives of sulfanilamide
US3334302A (en) * 1962-07-02 1967-08-01 Snc Science Union Et Cie Soc F Dicyclic sulfonylurea compounds
US20050257810A1 (en) * 2001-02-15 2005-11-24 Bigott James W Kitchenware washers and related methods
US20060237047A1 (en) * 2001-02-15 2006-10-26 Bigott James W Kitchenware washers and methods of manufacturing the same
US7527062B2 (en) * 2001-02-15 2009-05-05 Steelkor, L.L.C. Kitchenware washers and methods of manufacturing the same
US7578305B2 (en) 2001-02-15 2009-08-25 Steelkor, L.L.C. Kitchenware washers and related methods
US20040147430A1 (en) * 2001-06-02 2004-07-29 Philippe Briet Use of antidiabetics for making a medicine with cicatrizing effect
WO2003003971A2 (en) * 2001-06-20 2003-01-16 Merck Sante Use of antidiabetics for making a medicine with cicatrizing effect
WO2003003971A3 (en) * 2001-06-20 2003-12-04 Philippe Briet Use of antidiabetics for making a medicine with cicatrizing effect
US20050239887A1 (en) * 2002-01-25 2005-10-27 Ochoa Jose Manuel Francisco L Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
US9045438B2 (en) 2002-01-25 2015-06-02 Silanes S.A. De C.V. Pharmaceutical composition containing glimepiride and metformin hydrochloride
US20060237045A1 (en) * 2005-04-22 2006-10-26 Bigott James W Kitchenware washers and methods of manufacturing the same
US7475698B2 (en) 2005-04-22 2009-01-13 Steelkor, L.L.C. Kitchenware washers and methods of manufacturing the same
US20060254619A1 (en) * 2005-04-22 2006-11-16 Bigott James W Commerical kitchenware washers and related methods
US20060237046A1 (en) * 2005-04-22 2006-10-26 Bigott James W Kitchenware washers and methods of manufacturing the same
US7763119B2 (en) 2005-04-22 2010-07-27 Steelkor, L.L.C. Kitchenware washers and methods of manufacturing the same
US20100282281A1 (en) * 2005-04-22 2010-11-11 Steelkor, L.L.C. Kitchenware washers and methods of manufacturing the same
US9265400B2 (en) 2005-04-22 2016-02-23 Duke Manufacturing Co. Commercial kitchenware washers and related methods
US20070264331A1 (en) * 2005-09-08 2007-11-15 Laboratorios Silanes, S.A De C.V. Stable pharmaceutical composition of immediate-release glimepiride and extended-release metformin

Similar Documents

Publication Publication Date Title
Sneddon Adverse effect of topical fluorinated corticosteroids in rosacea
US3196078A (en) Process for combating retinits pigmentosa
SPIES et al. The use of nicotinic acid in the treatment of pellagra
US5767098A (en) Anti-acne method and composition
USRE37263E1 (en) Anti-inflammatory formulations for inflammatory diseases
Eaglstein et al. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster
US6063814A (en) Phorbol esters as anti-neoplastic and white blood cell elevating agents
Plewig et al. Anti-inflammatory effects of 13-cis-retinoic acid
US5519014A (en) Treatment of non-inflammatory and non-infectious bowel disorders
US4505896A (en) Method of treating acne vulgaris and composition
US5731325A (en) Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5510391A (en) Method of treating blood vessel disorders of the skin using vitamin K
US5374661A (en) Composition and method for transdermal delivery of diclofenac
US5962517A (en) Pharmaceutical compositions and methods for treating acne
Meyer et al. Production of Hypoprothrombinemia and Hypoeoagulability of the Blood with Salicylates.
US4512977A (en) Therapeutic selenium compositions and the use thereof
US4673691A (en) Human weight loss inducing method
US20080038219A1 (en) Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof
US4322438A (en) Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
US6399651B1 (en) Method of treating dermatoses using avermectin compound
Orfanos et al. Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis
US4588744A (en) Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide
US20040167084A1 (en) Dermatological composition and kit containing avermectin compound for treating dermatological conditions
WO1999009969A1 (en) Treatment of cell-mediated immune diseases
Nielsen A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea